- $114.16m
- $107.61m
- $46.66m
- 50
- 26
- 65
- 44
Annual income statement for Genasys, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | C2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 37 | 43 | 47 | 54 | 46.7 |
Cost of Revenue | |||||
Gross Profit | 18.5 | 22.6 | 23.4 | 27.3 | 21.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 33.8 | 37 | 45.9 | 69.6 | 57.6 |
Operating Profit | 3.14 | 6.04 | 1.08 | -15.5 | -11 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.36 | 6.17 | 1.14 | -15.5 | -11 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.78 | 11.9 | 0.704 | -16.2 | -18.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 2.78 | 11.9 | 0.704 | -16.2 | -18.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 2.78 | 11.9 | 0.704 | -16.2 | -18.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.083 | 0.348 | 0.023 | -0.21 | -0.498 |